About Phaeosynt
Our mission: Animal-free. Innovative. High quality.
At Phaeosynt, we have made it our mission to rethink antibody production: away from animal models and towards an environmentally friendly and resource-saving diatom platform. With our interdisciplinary team of biotechnologists, chemists and economists, we are shaping the future of diagnostics and research – always under the highest quality and ethical standards.
About us
Foundation
Founded in 2023 by a team of biotechnologists and economists in Hanover, Phaeosynt started out with the idea of producing antibodies in diatoms instead of in animals or animal cell cultures.
Our milestones
- 2021: Start of the development of animal-free antibody production based on diatoms
- 2022: Receipt of the start-up grant, development of the first pregnancy antibodies, establishment of the first production processes on a laboratory scale
- 2023: Further development of pregnancy antibodies, development of the vegan pregnancy test, closing of the pre-seed round
- 2024: Validation of the pregnancy test, establishment of the interdisciplinary team, start of initial research and cooperation projects, funding commitments from partners and institutions
- 2025: Closing of the seed round, preparation of series production of hey mela®, start of the market launch of hey mela®, preparation of internationalization and antibody scaling
Our team
Behind every success are people: Get to know our experts – from antibody development to product quality and business development. Together, we create innovations that combine passion and responsibility.
Stephanie Pfeil-Coenenen
CEO, Management, Finance, Sales
Dr. Alina Eilers
COO, management, cooperations, QM
Stas Hans
CTO, Research, Development
Leonard Käufler
Research developer
Hanna Hiller
Biological-technical assistant
Ilka Kerren
Cloning expert
Yazan Horani
Working student Finance
Luca Hoffmann
Production specialist
Natalie Gramann
Business Development
Tim Müller
Working student social media
Björn Burdorf
Content Creation
Stephanie Pfeil-Coenenen
CEO, Management, Finance, Sales
Dr. Alina Eilers
COO, Management, Marketing, Quality Management
Stas Hans
CTO, Research, Development
Eva-Maria Plönnigs
Head of Production, Laboratory and Production Management
Lina Altmann
Online Marketing Manager
Ilka Kerren
Production Manager, cloning and upstream expert
Leo Käufler
Research developer
Johanna Temps
Working student for production management
Luca Hoffmann
Biological-technical assistance
Our advisory board
Dr. Maren Wichmann
The molecular biologist has been working on recombinant antibodies and heterologous protein production at Leibniz Universität Hannover since completing her doctorate. She teaches genetics and molecular biology there.
Jannis Abram
Financing expert and representative of PSD Bank with many years of experience in supporting high-growth companies. His focus is on corporate financing, strategic scaling and the development of sustainable growth models.
Dr. Ingo Dahm
Digital pioneer from the very beginning, business angel and investor in Impact Startups with his company capacura GmbH
Katharina Borchert
Journalist, former Managing Director at Spiegel Online and Chief Innovation Officer at Mozilla Corporation.
Dr. Gunter Dunkel
Economist and entrepreneur, including member of the Supervisory Board of Continental AG, Managing Director of dunkel.investments and former Chairman of the Management Board of NordLB Hannover.
Dr. Maren Wichmann
The molecular biologist has been working on recombinant antibodies and heterologous protein production at Leibniz Universität Hannover since completing her doctorate. She teaches genetics and molecular biology there.
Jannis Abram
Financing expert and representative of PSD Bank with many years of experience in supporting high-growth companies. His focus is on corporate financing, strategic scaling and the development of sustainable growth models.
Dr. Ingo Dahm
Digital pioneer from the very beginning, business angel and investor in Impact Startups with his company capacura GmbH
Katharina Borchert
Journalist, former Managing Director at Spiegel Online and Chief Innovation Officer at Mozilla Corporation.
Dr. Gunter Dunkel
Economist and entrepreneur, including member of the Supervisory Board of Continental AG, Managing Director of dunkel.investments and former Chairman of the Management Board of NordLB Hannover.
Mission
We develop 100% animal-free antibody solutions that deliver the highest purity, cost efficiency and reproducible quality using state-of-the-art diatom biotechnology. We consistently focus on sustainability – from the cultivation of the algae to the end product.
Vision
Our goal is to establish Phaeosynt as the global standard for ethical and highly scalable antibodies. We are driving the global spread of animal-free diagnostics and thus enabling a paradigm shift in research, medicine and industry.
